financetom
Business
financetom
/
Business
/
Stifel Canada on WELL Health Q3 Organic Growth Figures
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stifel Canada on WELL Health Q3 Organic Growth Figures
Nov 21, 2025 10:56 AM

01:44 PM EST, 11/21/2025 (MT Newswires) -- On Thursday, WELL Health Technologies ( WHTCF ) disclosed organic growth figures for its Canadian clinic network for the third-quarter. Total quarterly organic growth across WELL Medical Centres (WMC, Primary Care) was 16%, consisting of 10% same-clinic organic growth and growth from the clinic absorption program of 6%, notes analyst Justin Keywood.

WELL Diagnostic Centres (WDC, Specialty) showed organic growth of 16%. This compares to consolidated organic growth of 8% in the third-quarter of last year, and 18% in the second-quarter of 2025. This shows the continued strength of WELL's core clinic business and its capacity to augment existing and acquired clinic revenue generation and drive same-clinic growth through optimizing physicians' workflow and capacity, Keywood adds.

Well Health ( WHTCF ) is rated Buy, with a $9 price target.

Price: 3.87, Change: +0.04, Percent Change: +0.91

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
Sep 8, 2025
04:27 AM EDT, 09/08/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that results from a phase 3 trial of Tagrisso plus pemetrexed and platinum-based chemotherapy showed statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival compared with Tagrisso alone in patients with non-small cell lung cancer. The Tagrisso combination therapy showed a median...
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Sep 8, 2025
04:03 AM EDT, 09/08/2025 (MT Newswires) -- Alkermes ( ALKS ) said Sunday that a phase 2 study of its investigational drug alixorexton in patients with type 1 narcolepsy showed clinically meaningful and statistically significant improvements in wakefulness, cognition and fatigue that were sustained over a six-week treatment period. The 92-patient study met its primary endpoint of improvements in mean...
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
Sep 8, 2025
Sept 8 (Reuters) - STRATHCONA RESOURCES ( STHRF ): * STRATHCONA RESOURCES ( STHRF ) - MEG BOARD DEAL IS UNFAIR TO MEG SHAREHOLDERS AND RESULT OF A BROKEN SALE PROCESS * STRATHCONA RESOURCES LTD. ( STHRF ) ANNOUNCES AMENDED AND EXTENDED OFFER TO ACQUIRE MEG ENERGY CORP. * STRATHCONA RESOURCES LTD ( STHRF ) - AMENDED OFFER EQUATES TO...
Chevron seeks diversified approach to refinery investment
Chevron seeks diversified approach to refinery investment
Sep 8, 2025
SINGAPORE, Sept 8 (Reuters) - Chevron ( CVX ) is looking to have a balanced portfolio of refineries, Brant Fish, the U.S. major's president, international products, said at the APPEC event in Singapore. There'll be places like Korea where we go investment heavy in petrochemicals and in heavy oil upgrading, Fish said of the firm's existing investments. And then there'll...
Copyright 2023-2025 - www.financetom.com All Rights Reserved